These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 35226112)

  • 1. A clinical scoring tool validated with machine learning for predicting severe hand-foot syndrome from sorafenib in hepatocellular carcinoma.
    Abuhelwa AY; Badaoui S; Yuen HY; McKinnon RA; Ruanglertboon W; Shankaran K; Tuteja A; Sorich MJ; Hopkins AM
    Cancer Chemother Pharmacol; 2022 Apr; 89(4):479-485. PubMed ID: 35226112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hand-foot syndrome due to sorafenib in hepatocellular carcinoma treated with vitamin E without dose modification; a preliminary clinical study.
    Bozkurt Duman B; Kara B; Oguz Kara I; Demiryurek H; Aksungur E
    J BUON; 2011; 16(4):759-64. PubMed ID: 22331734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma.
    Yada M; Masumoto A; Motomura K; Tajiri H; Morita Y; Suzuki H; Senju T; Koyanagi T
    World J Gastroenterol; 2014 Sep; 20(35):12581-7. PubMed ID: 25253961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. β-Hydroxy-β-methyl Butyrate/L-Arginine/L-Glutamine Supplementation for Preventing Hand-Foot Skin Reaction in Sorafenib for Advanced Hepatocellular Carcinoma.
    Naganuma A; Hoshino T; Ohno N; Ogawa Y; Murakami T; Horiguchi S; Uehara D; Suzuki Y; Hatanaka T; Kudo T; Ishihara H; Sato K; Kakizaki S; Takagi H
    In Vivo; 2019; 33(1):155-161. PubMed ID: 30587616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hand-Foot Syndrome and Post-Progression Treatment Are the Good Predictors of Better Survival in Advanced Hepatocellular Carcinoma Treated with Sorafenib: A Multicenter Study.
    Ogawa C; Morita M; Omura A; Noda T; Kubo A; Matsunaka T; Tamaki H; Shibatoge M; Tsutsui A; Senoh T; Nagano T; Takaguchi K; Tani J; Morishita A; Yoneyama H; Masaki T; Moriya A; Ando M; Deguchi A; Kokudo Y; Minami Y; Ueshima K; Sakurai T; Nishida N; Kudo M
    Oncology; 2017; 93 Suppl 1():113-119. PubMed ID: 29258090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of urea cream on sorafenib-associated hand-foot skin reaction in patients with hepatocellular carcinoma: A multicenter, randomised, double-blind controlled study.
    Lee YS; Jung YK; Kim JH; Cho SB; Kim DY; Kim MY; Kim HJ; Seo YS; Yoon KT; Hong YM; Lee JH; Lee HW; Yim HJ; Jang BK; Jang ES; Jang JY; Hwang SY
    Eur J Cancer; 2020 Nov; 140():19-27. PubMed ID: 33039810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hand-foot-skin reaction of grade ≥ 2 within sixty days as the optimal clinical marker best help predict survival in sorafenib therapy for HCC.
    Wang E; Xia D; Bai W; Wang Z; Wang Q; Liu L; Wang W; Yuan J; Li X; Chen H; Lv Y; Niu J; He C; Guo W; Yin Z; Luo B; Han N; Wang Z; Yu T; Yuan X; Li K; Tie J; Li C; Cai H; Xia J; Fan D; Han G
    Invest New Drugs; 2019 Jun; 37(3):401-414. PubMed ID: 30019101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased cumulative doses and appearance of hand-foot skin reaction prolonged progression free survival in sorafenib-treated advanced hepatocellular carcinoma patients.
    Chang WT; Lu SN; Rau KM; Huang CS; Lee KT
    Kaohsiung J Med Sci; 2018 Jul; 34(7):391-399. PubMed ID: 30063012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial.
    Park JW; Kim YJ; Kim DY; Bae SH; Paik SW; Lee YJ; Kim HY; Lee HC; Han SY; Cheong JY; Kwon OS; Yeon JE; Kim BH; Hwang J
    J Hepatol; 2019 Apr; 70(4):684-691. PubMed ID: 30529387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preventive effect of celecoxib in sorafenib-related hand-foot syndrome in hepatocellular carcinoma patients, a single-center, open-label, randomized, controlled clinical phase III trial.
    Chen JC; Wang JC; Pan YX; Yi MJ; Chen JB; Wang XH; Fu YZ; Zhang YJ; Xu L; Chen MS; Zhang RX; Zhou ZG
    Am J Cancer Res; 2020; 10(5):1467-1476. PubMed ID: 32509392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.
    Bruix J; Raoul JL; Sherman M; Mazzaferro V; Bolondi L; Craxi A; Galle PR; Santoro A; Beaugrand M; Sangiovanni A; Porta C; Gerken G; Marrero JA; Nadel A; Shan M; Moscovici M; Voliotis D; Llovet JM
    J Hepatol; 2012 Oct; 57(4):821-9. PubMed ID: 22727733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma.
    Lee JH; Chung YH; Kim JA; Shim JH; Lee D; Lee HC; Shin ES; Yoon JH; Kim BI; Bae SH; Koh KC; Park NH
    Cancer; 2013 Jan; 119(1):136-42. PubMed ID: 22736425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
    Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
    Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor Hypervascularity and hand-foot-skin reaction predict better outcomes in combination treatment of TACE and Sorafenib for intermediate hepatocellular carcinoma.
    Wang E; Xia D; Bai W; Yuan J; Li X; Niu J; Yin Z; Xia J; Cai H; Fan D; Han G; Liu L
    BMC Cancer; 2019 Apr; 19(1):409. PubMed ID: 31039750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Relationship between albumin-Bilirubin grade and survival in hepatocelluler carcinoma patients treated with sorefanib.
    Fidan E; Fidan S; Merev E; Kazaz N
    Niger J Clin Pract; 2022 Feb; 25(2):173-177. PubMed ID: 35170443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship Between Adverse Events and Microbiomes in Advanced Hepatocellular Carcinoma Patients Treated With Sorafenib.
    Yamamoto K; Kuzuya T; Honda T; Ito T; Ishizu Y; Nakamura M; Miyahara R; Kawashima H; Ishigami M; Fujishiro M
    Anticancer Res; 2020 Feb; 40(2):665-676. PubMed ID: 32014907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hand-foot skin reaction is a beneficial indicator of sorafenib therapy for patients with hepatocellular carcinoma: a systemic review and meta-analysis.
    Wang P; Tan G; Zhu M; Li W; Zhai B; Sun X
    Expert Rev Gastroenterol Hepatol; 2018 Jan; 12(1):1-8. PubMed ID: 28847184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-centre, prospective study.
    Howell J; Pinato DJ; Ramaswami R; Bettinger D; Arizumi T; Ferrari C; Yen C; Gibbin A; Burlone ME; Guaschino G; Sellers L; Black J; Pirisi M; Kudo M; Thimme R; Park JW; Sharma R
    Aliment Pharmacol Ther; 2017 Apr; 45(8):1146-1155. PubMed ID: 28252185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma.
    Lin SM; Lu SN; Chen PT; Jeng LB; Chen SC; Hu CT; Yang SS; Le Berre MA; Liu X; Mitchell DY; Prins K; Grevel J; Peña CA; Meinhardt G
    Hepatol Int; 2017 Mar; 11(2):199-208. PubMed ID: 27909950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib: a review of its use in advanced hepatocellular carcinoma.
    Keating GM; Santoro A
    Drugs; 2009; 69(2):223-40. PubMed ID: 19228077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.